Day: October 26, 2025

Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor UpdateFaraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FF Finance Company has Been Established and Completed its Financial License Application; BlackRock has Further Increased its Holdings in FFAI; The First Superstar Owner of the FX Super One is About to be Revealed.The UAE launch of the FX Super One will take place on October 28 at the Armani Hotel, Burj Khalifa, Dubai.LOS ANGELES, Oct. 26, 2025 (GLOBE NEWSWIRE) — Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global shared intelligent electric mobility ecosystem company, today shared a weekly business update from YT Jia, Founder and Global Co-CEO of FF. “Welcome to the 26th issue of our Weekly Report. First,...

In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes and who have confirmed amyloid pathology TOKYO and CAMBRIDGE, Mass., Oct. 26, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (lecanemab) for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia...

ALAMEDA, Calif., Oct. 26, 2025 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the pricing of a best efforts registered direct offering of 6,000,000 shares of its common stock at an offering price of $1.62 per share and concurrent private placement of 3,703,703 shares of its common stock at an offering price of $1.62 per share purchased by Gregg Williams, the Chairman of the Company’s board of directors. The registered offering and the private placement were priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC. The gross proceeds to the Company from the registered offering and private placement are expected to be approximately $15.7 million, before...

Latest assays include 43m at 7.6% CuEq and 15m at 16% CuEq; The vast majority of this rich core, which remains open, sits outside the current Mineral Resource Green Bay Copper-Gold Project, Canada KEY POINTSAn extremely high-grade core is emerging at Green Bay, with the drilling results continuing to reveal the presence of this rich copper-gold mineralisation over substantial widths along an 800m length This high-grade core, which remains open along strike, stands to significantly impact the Mineral Resource Estimate planned for release this quarter and the subsequent economic studies Drilling suggests the core occurs where the Volcanogenic Massive Sulphide (VMS) and Footwall Zone (FWZ) style mineralisation converge The latest holes into the high-grade core have returned intersections of:43.6m @ 7.6% copper equivalent (CuEq)1 (5.7%...

Continued strong performance of Perseus Mining’s operations grows cash & bullion balance to US$827 million Perth, Oct. 27, 2025 (GLOBE NEWSWIRE) — SEPTEMBER 2025 QUARTER REPORT Perseus Mining’s sustained operational performance grows         cash & bullion balance to US$837 million PERTH, Western Australia/October 27, 2025/Perseus Mining Limited (“Perseus” or the “Company”) (TSX & ASX: PRU) reports on its activities for the three months’ period ended September 30, 2025 (the “Quarter”). Below is a summary of the release. The full report is available at www.perseusmining.com, www.sedarplus.ca and www.asx.com.au. Operating performance12-month rolling average TRIFR of 0.60 well below industry average. Gold produced totalled 99,953 ounces at an AISC of US$1,463 per ounce. Average cash margin of US$1,612 per ounce of...

The offering is being fully subscribed by two new fundamental investment managers Company’s pro-forma cash position expected to be in excess of US$300 million following closingTORONTO, Oct. 26, 2025 (GLOBE NEWSWIRE) — POET Technologies Inc. (NASDAQ: POET) (the “Company”), the designer and developer of the POET Optical Interposer™, Photonic Integrated Circuits (PICs) and light sources for the data center, tele-communication and artificial intelligence markets, today announced that it has entered into securities purchase agreements with institutional investors for the purchase and sale of 20,689,655 common shares in an oversubscribed registered direct offering. The offering is expected to result in gross proceeds of approximately US$150 million, before deducting offering expenses. The closing of the offering is expected...

Nick Kwong moves from COO to CEO/President; Updated economic studies and resource growth at centre of strategy to drive value creation TORONTO and PERTH, Australia, Oct. 26, 2025 (GLOBE NEWSWIRE) — Cygnus Metals Limited (ASX: CY5; TSXV: CYG; OTCQB: CYGGF) (“Cygnus” or the “Company”) is pleased to announce that Chief Operating Officer “COO”) Nick Kwong will be promoted to President/Chief Executive Officer (“CEO”) of the Company following the transition of Ernest Mast from Managing Director to Non-Executive Director on 12 December 2025. Mr Kwong is a globally experienced Mining Engineer who has led operations, feasibility studies and mine building activities over the past 20 years. He has been COO of the Chibougamau Project since 2022 and has worked extensively with Mr Mast over this time. His previous positions include General Manager...

SAN FRANCISCO and BOSTON, Oct. 26, 2025 (GLOBE NEWSWIRE) — MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced the pricing of its initial public offering of 14,750,000 shares of common stock at an initial public offering price of $17.00 per share. In addition, MapLight has granted the underwriters a 30-day option to purchase up to an additional 2,212,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. In addition to the shares sold in the initial public offering, MapLight announced a concurrent sale of 476,707 shares of common stock at the initial public offering price per share in a private placement to affiliates of Goldman Sachs...

Regulated Information – inside information Nyrstar NV: Update on decision of the FSMA Sanctions Committee of 26 September 2025 26 October 2025 at 22:30 CET The Sanctions Committee of the Belgian Financial Services and Markets Authority (FSMA) issued a decision on 26 September 2025 in relation to the information disclosure by Nyrstar NV (the “Company”) on 30 October 2018. The Company provided a description of this decision in its press release of 28 September 2025 (see here). On the evening of Friday 24 October 2025, the Company was informed that certain shareholders had filed a petition earlier that day with the Market Court to appeal the Sanctions Committee’s decision. The shareholders have involved the Company and the directors who were in office on 30 October 2018 in their appeal. In their petition, the claimant shareholders request...

Research on TissueCypher by Horvath et al. honored with a Presidential Poster Award from the ACG Abstract Selection Committee, a distinction awarded to only 5-7% of abstracts for research deemed high quality, novel or unique FRIENDSWOOD, Texas, Oct. 26, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating that its TissueCypher® Barrett’s Esophagus test can provide risk insights beyond pathology alone, influencing clinical management to support earlier intervention for those at higher risk of progression to esophageal cancer and potentially reducing unnecessary procedures for those at lower risk. The research will be presented in three posters at the American College of Gastroenterology (ACG) 2025 Annual...